This hub began with a structural question: what is Medicare Advantage and what does it produce? Twelve articles of documented evidence later, the core questions have answers.
This article states what the evidence resolves, what it does not resolve, and where the deliberative question returns to the people who will ultimately decide it.
What the Evidence Resolves
On cost. The federal government paid $84 billion more for Medicare Advantage enrollees in 2025 than it would have cost to cover those same beneficiaries under traditional Medicare. That figure comes from MedPAC — the Medicare Payment Advisory Commission, the nonpartisan federal body Congress created to advise on Medicare payment policy. It is not a projection, not an advocacy estimate, not a disputed calculation. It is the government’s own accountants reporting on the program the government operates.
The overpayment has two documented components: benchmark rates set deliberately above traditional Medicare costs when the Medicare Modernization Act of 2003 created the current program, and a coding intensity gap generated by insurer-initiated diagnosis documentation that inflates risk-adjusted payments without corresponding treatment. GAO documented approximately $75 billion in overpayments over the prior decade in 2022. The trajectory is upward.
On the fraud mechanism. OIG documented that 99 percent of the highest-value risk adjustment diagnoses submitted by Medicare Advantage plans came from the insurer rather than the treating provider. That finding describes a payment system operating precisely as its financial incentives predict: rewarding documented diagnoses, not treated conditions. The Department of Justice has active or recently resolved enforcement actions against every major MA insurer — UnitedHealth Group (criminal prosecution), Kaiser Permanente ($556 million civil settlement), Humana ($90 million), Cigna ($172 million), CVS Health/Aetna (ongoing investigation) — for the same category of conduct across a program that is nominally competitive.
On what enrollees actually receive. OIG found that 13 percent of prior authorization requests denied by MA plans met Medicare coverage criteria; 18 percent of payment denials met those criteria. A nationally representative sample of the program’s 15 largest organizations, covering nearly 80 percent of enrollees, documented that the care traditional Medicare would have covered was denied by the private insurers administering the program in its place. More than half of MA enrollees are in HMO plans that cover no out-of-network care except in emergencies. More than 52 percent of MA provider directory listings contained at least one inaccuracy. MA enrollees requiring complex cancer surgery are less likely to be treated at specialized centers, experience longer delays, and have higher mortality than traditional Medicare beneficiaries, according to peer-reviewed research in the Journal of Clinical Oncology.
On what happens at the end of life. MA enrollees who develop serious illness disenroll back to traditional Medicare at substantially higher rates than the general MA population. In states with Medigap guaranteed-issue protections — where returning to traditional Medicare is financially feasible — the disenrollment rate following a serious health shock is nearly double the rate in states without those protections. The program’s financial structure attracts healthy enrollees at 65, collects capitated payments during the low-cost enrollment period, and transfers the highest-cost patients back to the public program when their care needs become most acute. GAO identified this disenrollment pattern in the last year of life in 2021 and flagged it as indicating possible issues with end-of-life care in the MA setting.
On what produced these outcomes. The evidence resolves the causal question as clearly as it resolves the descriptive one. These outcomes are not malfunctions of a program that was designed to work differently. They are the documented expression of a financial architecture whose incentives point precisely where the outcomes go. A capitated payment that rewards minimizing care delivered relative to payment received produces prior authorization denial of covered care, network restrictions that reduce access to expensive specialists, marketing designed to attract healthy enrollees who will use less care, and disenrollment of seriously ill patients whose care costs exceed what the capitated payment covers. Each of these is the rational response of a profit-maximizing organization to the incentive structure it was given.
The argument that government cannot administer healthcare efficiently is made, in current lobbying and congressional testimony, by organizations that extracted $84 billion from the government program they were hired to administer more efficiently. The record states this plainly.
What Single-Payer Resolves — and How Completely
Medicare Advantage is more directly a creature of a specific legislative decision than any other subject in this cluster of hubs. Hospital consolidation followed market logic over decades; the commercial insurance market developed through decades of private contracting; pharmaceutical pricing evolved through a combination of patent law, regulatory decisions, and market structure. Medicare Advantage was created in its current form by a vote of Congress in 2003 and could be ended by a vote of Congress at any point thereafter. The question of what a different legislative decision resolves is therefore more direct here than anywhere else in the cluster.
What single-payer eliminates by definition:
A single-payer system — in which the government pays providers directly for care delivered to all enrolled beneficiaries, as traditional Medicare currently does for its population — eliminates Medicare Advantage as a structural category. Not by reforming it. Not by regulating it more aggressively. By eliminating the payment structure it operates within.
Under a single-payer system:
There is no capitated rate paid to a private insurer. The mechanism that rewards minimizing care delivered does not exist.
There is no risk adjustment system for private insurers to exploit. The diagnosis-coding apparatus that generates the $84 billion annual overpayment has nothing to operate on.
There is no prior authorization authority in the hands of a private insurer whose financial interest is opposed to the beneficiary’s interest in comprehensive coverage. Coverage decisions are governed by the public program’s benefit design and the treating physician’s clinical judgment.
There is no provider network constructed to minimize cost and exclude high-volume specialty facilities. Any provider who accepts the public program’s rates — the structure traditional Medicare already operates — is covered.
There is no extra benefits enrollment hook designed to attract healthy 65-year-olds whose dental coverage needs are greater than their cardiac surgery needs. There is no product to market because there is no competing private insurer.
There is no Medigap lock-in because there is no MA enrollment to lock into. The mechanism that prevents seriously ill beneficiaries from accessing traditional Medicare’s unrestricted provider access disappears because the structure that created the lock-in disappears.
The $84 billion annual overpayment does not need to be recovered through better auditing — the mechanism that generates it does not exist. The prior authorization and denial patterns do not need to be regulated away — the financial interest that produces them does not exist. The marketing machine does not need to be constrained by marketing rules — there is no product to market.
This is not a projection about what single-payer would accomplish if it worked as intended. It is a description of what single-payer is: a system in which the government pays providers directly, eliminating the private insurer intermediary whose financial architecture this hub has documented. The elimination of that architecture eliminates the documented outcomes it produces. The logical connection is direct.
The evidence supports this conclusion in the strongest formulation the hub uses anywhere in the cluster. It is stated here without apology because the evidence warrants it.
What Single-Payer Does Not Resolve
The analytical honesty that warrants the strong formulation also requires stating what single-payer does not resolve. These are genuine limitations, not rhetorical gestures toward balance.
The Medicare benefit design questions. Single-payer financing does not determine what a comprehensive public benefit covers. The questions of whether traditional Medicare should be expanded to cover dental, vision, and hearing — the coverage gaps that MA advertising exploits — are independent of the financing mechanism. A single-payer system could be designed with or without those expansions. The Long-Term Care Financing hub documents the gap in long-term care coverage that exists independent of MA and would remain independent of single-payer. These are coverage scope questions, not financing mechanism questions.
Provider payment rates. How physician and hospital rates are set under a single public payer — whether at current traditional Medicare rates, at negotiated rates that differ from current Medicare, or at rates calibrated to sustain the provider capacity the population needs — is a consequential policy question that single-payer financing does not automatically answer. The Single-Payer Healthcare hub covers the evidence on rate-setting approaches and their documented effects in other countries. The elimination of MA does not resolve how traditional Medicare pays providers; it simply removes the private insurer layer between the government payment and the provider.
Rural provider capacity. MA network adequacy failures are most acute in rural markets where provider scarcity predates and is independent of MA. When MA disappears, the rural communities that have lost hospitals and specialists retain those losses. The Hospital Consolidation hub documents the closure pattern; the Long-Term Care hub documents the workforce and facility gaps. Single-payer financing addresses the payment mechanism, not the underlying capacity.
The political infrastructure already built. The 33 million Medicare Advantage enrollees who receive regular communications from their insurers about the program and its benefits, the lobbying operation of more than 220 Capitol Hill lobbyists, the $330 million in lobbying investment over five years, the campaign contribution network — none of this dissolves because a different legislative decision is made. The political obstacle to the legislative change is precisely what that infrastructure was built to create. Single-payer financing eliminates the program; it does not eliminate the industry’s capacity to prevent the legislative decision that would eliminate it.
The Loop This Hub Names Directly
This hub has documented a specific causal loop that connects the origin of Medicare Advantage to the difficulty of reforming or eliminating it.
The legislative decision in 2003 created a payment structure that generated an industry — an industry of insurers, brokers, vendors, and lobbyists whose revenues depend on the continuation of the program. That industry has spent the twenty years since 2003 building the enrollment base and political infrastructure that makes reform of the 2003 decision progressively more difficult. Thirty-three million enrolled beneficiaries receiving insurer communications are a political constituency. Two hundred twenty lobbyists on Capitol Hill are a political fact. Campaign contributions are a political reality.
The evidence that the program costs more, delivers less, and produces the documented patterns of fraud, denial, and disenrollment at the end of life has been available for most of that period. MedPAC’s concerns about the overpayment structure were documented before the MMA 2003 even passed. The evidence has not resolved the political question because the political question is not primarily about evidence. It is about the balance of organized interests operating year-round against the episodic, dispersed engagement of the beneficiaries and taxpayers who bear the costs.
This hub does not tell readers what to conclude from that observation. The forum is where people who have engaged with this evidence work out what it means for what they want to do. This article, and this hub, exist to ensure that engagement is informed by an accurate account of what the evidence shows.
The evidence is documented. The decision belongs to the public.
The complete Medicare Advantage series
01 — What Medicare Advantage Actually Is — and How It Replaced Traditional Medicare
02 — The Political History: How Private Insurers Got Into Medicare
03 — The Marketing Machine: How Enrollment Works and Who It Targets
04 — Risk Adjustment: The Payment System That Rewards Diagnosis, Not Treatment
05 — The $84 Billion Overpayment: How Upcoding Works at Scale
06 — The Profit Extraction Model: What Insurers Take Before Care Is Delivered
07 — Prior Authorization in Medicare Advantage: What OIG Found
08 — The Denial and Appeals Record: What Happens When Enrollees Push Back
09 — Network Adequacy and the Coverage Gap
10 — The Extra Benefits Myth: Dental, Vision, and What the Fine Print Says
11 — When Medicare Advantage Fails: Disenrollment at the End of Life
12 — The Reform Proposals: From Audit Reform to Elimination
13 — What the Evidence Resolves — and What It Doesn’t
This article was researched and drafted with AI assistance under human review. See our full AI and editorial practices.